Osteoporosis therapeutics: recent developments at ASBMR.
作者信息
Mallarkey Gordon, Reid David M
机构信息
Sage Publications Ltd, 1 Oliver's Yard, 55 City Road, London EC1Y 1SP, UK.
Emeritus Professor of Rheumatology, University of Aberdeen, Medical School, Foresterhill, Aberdeen, UK.
出版信息
Ther Adv Musculoskelet Dis. 2016 Feb;8(1):3-7. doi: 10.1177/1759720X15623489.
Abstract
摘要
相似文献
1
Osteoporosis therapeutics: recent developments at ASBMR.骨质疏松症治疗学：美国骨矿研究学会的最新进展
Ther Adv Musculoskelet Dis. 2016 Feb;8(1):3-7. doi: 10.1177/1759720X15623489.
2
[ASBMR 2010 report. Meeting report on the ASBMR: clinical topics in ASBMR 2010 at Toronto].
Clin Calcium. 2011 Jan;21(1):112-5.
3
4
[ASBMR 2010 report. Meeting report on the ASBMR. Present and future of the treatment of osteoporosis].
Clin Calcium. 2012 Jan;22(1):114-8.
5
[ASBMR 2009 Report. Meeting report on the ASBMR. ASBMR topics].[美国骨矿研究学会2009年报告。美国骨矿研究学会会议报告。美国骨矿研究学会主题]
Clin Calcium. 2010 Jan;20(1):108-11.
6
[ASBMR 2009 Report. Meeting report on the ASBMR. ASBMR topics].[美国骨矿研究学会2009年报告。关于美国骨矿研究学会的会议报告。美国骨矿研究学会主题]
Clin Calcium. 2010 Jan;20(1):112-5.
7
8
[ASBMR 2011 report. Meeting report on the ASBMR. Clinical topics in ASBMR 2011 at San Diego - vitamin D and calcium -].
Clin Calcium. 2012 Jan;22(1):111-3.
9
10
[ASBMR 2006 Report. Pathophysiology and diagnosis of osteoporosis].[美国骨矿研究学会2006年报告。骨质疏松症的病理生理学与诊断]
Clin Calcium. 2007 Jan;17(1):96-100.
引用本文的文献
1
Icariin Exerts Estrogen-Like Actions on Proliferation of Osteoblasts in Vitro via Membrane Estrogen Receptors-Mediated Non-nuclear Effects.淫羊藿苷通过膜雌激素受体介导的非核效应在体外对成骨细胞增殖发挥雌激素样作用。
Iran J Pharm Res. 2022 Aug 28;21(1):e127000. doi: 10.5812/ijpr-127000. eCollection 2022 Dec.
2
Management of adynamic bone disease in chronic kidney disease: A brief review.慢性肾脏病中动力缺失性骨病的管理：简要综述。
J Clin Transl Endocrinol. 2016 Jul 25;5:32-35. doi: 10.1016/j.jcte.2016.07.002. eCollection 2016 Sep.
本文引用的文献
1
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.地诺单抗治疗绝经后骨质疏松症女性8年或5年的效果：FREEDOM扩展研究结果
Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23.
2
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.奥达卡替治疗绝经后骨质疏松症：长期奥达卡替骨折试验（LOFT）的研发历程、设计及参与者特征
Osteoporos Int. 2015 Feb;26(2):699-712. doi: 10.1007/s00198-014-2944-6. Epub 2014 Nov 29.
3
Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.特立帕肽、地诺单抗及联合治疗对周围骨密度、微结构和估计强度的比较效应：DATA-HRpQCT研究
J Bone Miner Res. 2015 Jan;30(1):39-45. doi: 10.1002/jbmr.2315.
4
Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.绝经后骨质疏松症妇女使用地舒单抗和特立帕肽治疗 2 年（DATA 扩展研究）：一项随机对照试验。
J Clin Endocrinol Metab. 2014 May;99(5):1694-700. doi: 10.1210/jc.2013-4440. Epub 2014 Feb 11.
5
Romosozumab in postmenopausal women with low bone mineral density.罗莫佐单抗治疗绝经后低骨密度妇女。
N Engl J Med. 2014 Jan 30;370(5):412-20. doi: 10.1056/NEJMoa1305224. Epub 2014 Jan 1.
6
Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.特立帕肽和地舒单抗，单独或联合使用，治疗绝经后骨质疏松症女性：DATA 研究随机试验。
Lancet. 2013 Jul 6;382(9886):50-6. doi: 10.1016/S0140-6736(13)60856-9. Epub 2013 May 15.
Zotero 插件